



Non-fatal opioid overdose, naloxone access and naloxone training: The ETHOS Engage Study

Anna Conway

Heather Valerio, Amy Peacock, Louisa Degenhardt, Jeremy Hayllar, Mary Ellen Harrod, Charles Henderson, Phillip Read, Rosie Gilliver, Janaki Amin, Michael Christmass, Adrian Dunlop, Mark Montebello, Gilbert Whitton, David Reid, Thao Lam, Maryam Alavi, David Silk, Alison D Marshall, Gregory J Dore, Carla Treloar, and Jason Grebely

Funding Source / Disclosures

Funding Source: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings (ETHOS): Engage study is funded by a National Health & Medical Research Council Partnership Project grant, including funding from New South Wales Health, Cepheid and Merck/MSD.

Disclosures: none

Background/Aims

Background: Overdose is a major cause of morbidity and mortality among people who use opioids. Naloxone can reverse opioid overdoses and can be distributed and administered with minimal training.

Aims:

- To estimate (1) recent non-fatal opioid overdose (2) naloxone access and (3) naloxone training in people who recently used opioids or received opioid agonist treatment (OAT)
- To identify factors associated with (1), (2) & (3)

Background/Aims

Background: Overdose is a major cause of morbidity and mortality among people who use opioids. Naloxone can reverse opioid overdoses and can be distributed and administered with minimal training.

Aims:

- To estimate (1) recent non-fatal opioid overdose (2) naloxone access and (3) naloxone training in people who recently used opioids or received opioid agonist treatment (OAT)
- To identify factors associated with (1), (2) & (3)

Methods




ETHOS ENGAGE

ETHOS Engage- Wave I

May 2018 – September 2019

Recruitment: 1,443 people



This analysis: 1,280 people who recently (6 mo) used opioids or received OAT

Statistical analysis: Unadjusted and adjusted logistic regression models

Results: descriptive demographics (n=1,280)



65% male



Median age 43




22% Aboriginal and/or
Torres Strait Islander




10% homeless

Results: descriptive of key variables (n=1,280)

Drug use in last 6mo




Results: odds of recent non-fatal overdose (n=1,277)




Adjusted for: gender, age, ATSI, homelessness, prison history, site location, OAT duration, frequency of injecting, stimulant use (6 mo)

Results: odds of lifetime naloxone access (n=1,277)



Adjusted for: gender, age, ATSI, homelessness, prison history, site location, OAT duration, frequency of injecting, stimulant use (6 mo)


Results: odds of lifetime naloxone training (n=1,277)



Adjusted for: gender, age, ATSI, homelessness, prison history, site location, OAT duration, frequency of injecting, stimulant use (6 mo)

Results: lifetime naloxone access/ training in people with recent overdose

Two thirds of people who report recent overdose have never accessed naloxone



Conclusions

- Recent use of multiple depressant drugs is associated with non-fatal opioid overdose
- Naloxone access higher in people with recent use of multiple depressant drugs but low across the board
- Missed opportunity to train people attending OAT services
- Overdose is a predictor of subsequent overdose (Caudarella et al., 2016; Coffin et al., 2007; Forsyth et al., 2018)

Acknowledgements

All participants who have contributed their time and data to our study, and:

NUAA

Sara Adey
Rodd Hinton
Melanie Joyce

Youth Link

Needle and

Syringe

Program,

Cairns:

Astrid Carthew

Hepatitis South

Australia

Lisa Carter
Carol Holly

Harm Reduction

Western

Australia

Lyn Murphy



Acknowledgements

All participants who have contributed their time and data to our study, and:

Study co-authors

Heather Valerio	Thao Lam
Amy Peacock	Maryam Alavi
Louisa Degenhardt	David Silk
Jeremy Hayllar	Alison D Marshall
Mary Ellen Harrod	Gregory J Dore
Charles Henderson	Carla Treloar
Phillip Read	Jason Grebely
Rosie Gilliver	
Janaki Amin	
Michael Christmass	
Adrian Dunlop	
Mark Montebello	
Gilbert Whitton	
David Reid	

Kirby Institute

Indika Jayasinghe
Hannah Reid
Valerie Gleeson
Shane Tillakerante
Pip Marks
Yasmin Mowat

PSC

Nicky Bath
Emma Day
Nikitah Habraken
Kyle Leadbeatter
Clarke Scott
Jo Holden



Acknowledgements

All participants who have contributed their time and data to our study, and:

Site PIs

Nadine Ezard
David Reid
Carla Gorton
Michael Edwards
Jeremy Hayllar
Prasun Datta
Thao Lam
Alex Wade
Michael Christmass
Sally Spruce
Vicki Cock
Mark Cornwell
Craig Connelly
Mark Montebello
Angela Cooper
Adrian Dunlop



Robert Cherry
Julie Dyer
Shikha Arawal
Nadine Horasak
Rhondra Lewis
Kathy Clark
Daniel Morris
Kathy Donohue
Kathy Griffiths

Jason Dalla Lana
Sue Shin
Connie Graf
Adele Hampson
Carina Burns
Ravina Raidu
Kylie Stolzenhein
Wanda Brabender
Nargis Abram
Rick Turner



Site coordinators

Stuart Larter
Fiona Goodberg
Jennifer Luksza (
Michelle Hall
Susan Hazelwood
Krista Zohrab
Belinda McClurg
Kate Salisbury
Julie Markham
Jacky Talmet



Sandy Dunn
Fionnuala Smyth
Lisa Snell
Elizabeth Laing
Martin Clark
Justin Dorigo
Brent Fergusson
Bonny Puszka
Gai Duncan
Fiona Baker
Jayde Walsh



Hepatitis
NSW



ashm
Australasian Society for
HIV, Viral Hepatitis and
Sexual Health Medicine



Health